• Competitive intelligence lead for Phase 3 and Phase 2 immunology therapies (Sjogren’s, myositis, lupus)
• CI support for market research, brand planning, and medical affairs

• Led competitive intelligence efforts for on-market (GBM, MPM) and four Phase 3 pipeline solid tumor indications (NSCLC, ovarian, pancreatic, brain mets). Requires deep understanding of market landscape and turning scientific/clinical insights into actionable commercial strategy recommendations.
• Portfolio prioritization support in identifying, evaluating, and prioritizing indication expansion opportunities and selection of promising combination partners. Included market sizing forecasts (patient prevalence) to rank opportunities.
• Partnered with Business Development team to identify and assess commercial partners and clinical trial collaborators
• Leader for scenario planning / situational analysis workshops to guide competitive readiness strategy for commercial teams
• Provided ad hoc project support to CCO, CMO, CSO, and Clinical Development initiatives (e.g., evidence generation strategy [clinical and preclinical] and clinical trial design)

Senior Analyst at inThought Research providing analytical, forecasting, and competitive intelligence services that support the strategic decisions of biotech, pharmaceutical, and institutional investor firms.

• Conducted KOL due diligence calls on behalf of a hedge fund assessing the prospects of an oncology investment
• Customized immuno-oncology CI monitoring, analysis, and medical conference coverage for biopharma clients

www.inthought.com

• Pharmaceutical/biotech management consulting at Acsel Health, specializing in drug pricing and market access, business development, and new product commercialization strategies.
• Led an indication prioritization assessment to expand the label of a monoclonal antibody for use in allergic diseases
• Created physician and payer discussion guides to assess the commercial opportunity for an antibody therapy

Sell-side large cap. biotechnology equity research coverage for Leerink Partners, a healthcare focused investment bank. Experience in prescription trend analysis (IMS Health), drug pricing (PriceRx), competitive landscape mapping, clinical trial result assessment, and research note publication.

Led research aimed at identifying biomarkers in several rheumatic diseases. Patient serum was profiled with a high-throughput protein microarray to identify candidate biomarkers. The discovery of these biomarkers has the potential to for clinical applications that will aid physicians in the correct diagnosis and accurate prognosis.

Pioneered implementation and data analysis for a novel microarray technology. Developed a metric to analyze 3.4 million data points in Excel.

•Health sciences focused buy side equity research analyst program. Analyzed the biotechnology sector to find undervalued investment opportunities. Developed models of market sizing, revenue forecasting, earnings per share estimates, and a discounted cash flow analysis to determine an appropriate valuation. Recommendations were contingent on a detailed pipeline analysis and assessing the likelihood of an FDA approval for new therapies.

•1st place, stock pitch competition.